Mr. John Zehner

• 
  www.shaazamstocks.com/profiles/posc/management.php - [Cached Version]
  Published on: 8/15/2008    Last Visited: 8/15/2008  

  John ZehnerPresident, Positron Pharmaceuticals
  
  Mr. Zehner has over 14 years of experience in the Nuclear Medicine field.John has been part of several start-ups, mergers and acquisitions.In 1993, he assisted in the start-up of Northern Virginia Isotopes, Inc., a nuclear pharmacy focused on distributing radioactive pharmaceuticals for diagnostics and therapy to the Washington D.C. market.In 1994, he established Valley Isotopes, Inc., a nuclear pharmacy in Winchester, Virginia, Inc.In 1995, John led the formation of Eastern Isotopes, Inc. through the merger of three nuclear pharmacies and later established its pharmaceutical manufacturing division for FDG in 1998.In 1999, he became President and COO of Eastern Isotopes, Inc. and under his leadership grew sales from approximately $4 million to over $34 million by 2003.In 2004, Mr. Zehner led the extremely lucrative sale of Eastern Isotopes, Inc. to IBA, SA, a Belgium life science company.

• 
  www.engelpub.com/News/index.cfm?articleid=548596&catego - [Cached Version]
  Published on: 6/12/2008    Last Visited: 6/16/2008  

  John Zehner, President and Founder of NukeMed, Inc. and Dose Shield Corporation, has been named as President and Director of Positron Pharmaceuticals.
  ...
  Our products fully complement each other," said John Zehner, President and Founder of NukeMed, Inc. and Dose Shield Corporation.Zehner also stated, "We believe Positron is in an ideal position to offer a complete turnkey service into the Nuclear Cardiology market.
  ...
  In addition, Mr. Zehner executed a three year employment agreement with Positron to head Positron Pharmaceuticals.

• 
  houston.bizjournals.com/houston/stories/2008/06/09/dail - [Cached Version]
  Published on: 6/12/2008    Last Visited: 6/12/2008  

  John Zehner, president and founder of NukeMed and Dose Shield Corp., will head Positron Pharmaceuticals under a three-year agreement.
  
  "Joining forces with Positron makes perfect sense for NukeMed Inc. and Dose Shield Corp.Our products fully complement each other," Zehner said.

• 
  www.dimag.com/scanbusinessdaily/showArticle.jhtml?cid=D - [Cached Version]
  Last Visited: 6/17/2008  

  John Zehner, president and founder of NukeMed and Dose Shield, will serve as president and director.

• 
  www.perfusionplus.com/contactus.htm - [Cached Version]
  Last Visited: 4/28/2008  

  John Zehner, R.Ph.President and CEOjzehner@nukemed.com

• 
  ADAC Laboratories - [Cached Version]
  Published on: 11/27/2000    Last Visited: 9/2/2002  

  "This is an exciting partnership for us," said John Zehner, president of Eastern Isotopes."We believe the market for PET imaging is primed for exceptional growth.This will give us the opportunity to help advance PET technology by providing exactly what ADAC customers need, at the best possible prices."
  
  PET, or positron emission tomography, is an effective imaging technology used to diagnose and monitor certain cancers, cardiac diseases and brain disorders.It is an accurate, non-invasive method of determining malignancy and one of the few such methods available to determine whether a cancer has metastasized or spread beyond the original tumor site.After years of compelling clinical research, PET scans have now begun to find broader clinical acceptance.

• 
  June 18, 2002 - [Cached Version]
  Published on: 6/18/2002    Last Visited: 7/14/2004  

  Eastern Isotopes, Inc. welcomes the opportunity to supply FDG for Premier Hospitals across the Nation," states John Zehner, President of Eastern Isotopes, Inc.Zehner continues to say, "we look forward to this partnership with Premier.
  ...
  With the recent indications approved by HCFA, PET scanning will become mainstream in the diagnosis and staging of certain cancers," declared John Zehner, President of Eastern Isotopes, Inc.

• 
  LuXPoint, Finance - [Cached Version]
  Published on: 11/26/2000    Last Visited: 3/11/2001  

  With the recent indications approved by HCFA ( Health Care Financing Administration ) , PET scanning will become mainstream in the diagnosis and staging of certain cancers , declared John Zehner , President of Eastern Isotopes , Inc. The core competencies of our two companies uniquely position us to face the challenges of the expanding nuclear medicine market.The result is continuing expansion in cancer diagnostics and therapies while increasing a position in the cardiology and neurology markets.IBA is a perfect fit for our expansion..
  
  Currently , Eastern Isotopes , Inc. has cyclotrons based near Washington , D.C. and near Chicago , Illinois.Late last year , it has taken over the management responsibility of the cyclotron that West Virginia University owns in Morgantown , West Virginia.

• 
  NukeMed, Inc. Overview - [Cached Version]
  Published on: 6/30/2005    Last Visited: 1/22/2007  

  John Zehner, President and CEO
  
  John Zehner has over 14 years of experience in the Nuclear Medicine field.Mr. Zehner has been part of several start-ups and mergers/acquisitions in his field.In 1993, he assisted in the start-up of Northern Virginia Isotopes, Inc., a nuclear pharmacy focused upon distributing radioactive pharmaceuticals for diagnosis and therapy to the Washington D.C. market.In 1994, Mr. Zehner established a nuclear pharmacy in Winchester, Virginia called Valley Isotopes, Inc.In 1995, he led the merger of three nuclear pharmacies to form Eastern Isotopes, Inc.In 1998, he led the start-up of the pharmaceutical manufacturing division for FDG within Eastern Isotopes, Inc.
  
  In 1999, Mr. Zehner became President and COO of Eastern Isotopes, Inc.In that capacity, Mr. Zehner grew the company from a regional distribution pharmacy serving the Washington DC metro area to a national pharmaceutical manufacturing, imaging and distribution company serving more than 26 states.
  
  Under Mr. Zehner's leadership, Eastern's sales grew from approximately 4 million USD in 1998 to over 34 million USD in 2003.During this period, the company also grew from 3 nuclear pharmacies and 50 employees to 14 facilities consisting of pharmaceutical manufacturing plants, nuclear medicine imaging clinics and nuclear pharmacies with approximately 300 employees.
  
  In 2001, Mr. Zehner led the sale of Eastern Isotopes, Inc. to IBA, SA, a Belgium life science company, with an earn-out period.The exact terms of the sale remain confidential.During the earn-out period, Mr. Zehner had advisory responsibilities for IBA S. A. affiliates in France, Italy and Belgium.
  
  Mr. Zehner regularly presented overviews of Eastern Isotopes, Inc. to academic institutions, investors, large clients and other nuclear medicine vendors.He delivered an educational presentation to the Institute of Clinical PET (currently the Academy of Molecular Imaging) on the topic of opportunities in cyclotrons.He presented on behalf of Eastern Isotopes, Inc., who was ultimately awarded the largest contract for FDG at the time with a group purchasing organization (GPO), the GPO represented over 1500 hospitals.Eastern Isotopes, Inc. developed joint ventures with the University of West Virginia, the Medical College of Virginia and ADAC (recently acquired by Phillips) during Mr. Zehner's tenure.
  
  Mr. Zehner's background includes includes extensive experience in regulatory affairs with the Nuclear Regulatory Commission (NRC), the Food and Drug Administration (FDA), the Department of Transportation (DOT) and various state pharmacy boards.He has developed and presented budgets, financial projections and market forecasts to investors and various financial institutions on numerous occasions.Mr. Zehner's background also includes hands on experience as a nuclear pharmacist in 5 different states and as a radiation safety officer for 4 different companies, including Eastern Isotopes, Inc. and Amersham Health.He also has direct experience as a cyclotron operator for drug manufacturing.

• 
  PharmaLive: Business Strategy - [Cached Version]
  Published on: 6/12/2008    Last Visited: 6/13/2008  

  John Zehner, President and Founder of NukeMed, Inc. and Dose Shield Corporation, has been named as President and Director of Positron Pharmaceuticals. [more]

Page:  1 2